AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 291 min read$MEDP

Troendle August J. sold $1.6M of MEDP

Troendle August J. (President & CEO) sold 2,564 shares of Medpace Holdings, Inc. (MEDP) at an average of $620.10 ($620.07–$620.60, $1.59M total) across 2 trades over 2026-09-25 to 2026-09-28.

Original reporting
SEC EDGAR · Troendle August J.
Published Sep 29, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MEDP
Bearish
medium confidence
Mentioned
$MEDP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDPBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, which traders may use to adjust short‑term positions.

02

Market read

New insider sale information, modest in size, may cause slight price movement.

03

What to watch

Potential upcoming capital raise or strategic transaction that prompted the insider to free cash.

Relevance 6/10Novelty 5/10Timing: post‑market filing

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$MEDPBearishMedium confidence
Context

CEO August Troendle sold 2,564 shares of Medpace for $1.59M, reducing his stake to 386,892 shares.

Expected impact

likely slight downward pressure as the market prices in the insider sell

Evidence & confidence

A $1.6M open‑market sale by the CEO is material enough to affect sentiment, but the amount is modest relative to market cap.

Market effects

Sector

Minimal impact on the broader biotech/clinical‑trial services sector.

Regional

Limited to U.S. investors tracking insider activity.

Global

Low; does not affect global markets.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move unrelated to company fundamentals.

Key entities

  • company
    Medpace Holdings, Inc.

    U.S. clinical‑trial services provider.

  • person
    August J. Troendle

    President & CEO of Medpace.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MEDP insider trading history →

Related articles

OCT 23
$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

finance.yahoo.com2 min
OCT 22
$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

tradingview.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

finance.yahoo.com2 min
OCT 22
$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

finance.yahoo.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.

investing.com2 min